Premark has successfully completed a series of financing rounds which have established the business entity.

Premark’s lead investor is a consortium of predominantly US-based ophthalmologists. The group is represented on the Board of Directors by William Stewart, himself an ophthalmologist, with considerable experience in supporting start-ups in the ophthalmology space.

In December 2021, a partnering agreement, with associated milestone payments, was signed. This granted exclusive rights for the Phase 3 development and commercialisation of PMP2207 in blepharitis.

Premark is now seeking additional financial support for the Phase 3 programme for PMP1606 in dry eye/ocular surface inflammation.

Please contact us for more information.